Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects

Background: despite well-studied safety profile of dabigatran its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD). This study was aimed to evaluate relationships between CES1 and ABCB1 polymorphism, dabigatran...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: A. I. Skripka, P. O. Bochkov, K. A. Akmalova, R. V. Shevchenko, P. M. Krupenin, V. V. Kogay, A. I. Listratov, A. S. Krainyaya, D. A. Napalkov, O. S. Gurinovich, A. A. Sokolova, V. V. Fomin, D. A. Sychev
Fformat: Artigo
Iaith:Russo
Cyhoeddwyd: Remedium Group LLC 2020-01-01
Cyfres:Медицинский совет
Pynciau:
doac
dabigatran
atrial fibrillation
chronic kidney disease
hemorrhagic events
abcb1
ces1
rs1045642
rs2244613
rs4148738
pharmacokinetics
pharmacogenetics
Mynediad Ar-lein:https://www.med-sovet.pro/jour/article/view/5476
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg